Brian I. Carr, Venkateswarlu Kondragunta, Shama C. Buch and Robert A. Branch Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma Cancer 116
Version of Record online: 11 JAN 2010 | DOI: 10.1002/cncr.24884
Consecutive cohorts of patients (n = 932) with unresectable hepatocellular carcinoma (HCC) underwent either repeated, cisplatin-based chemoembolization or transhepatic arterial chemoembolization (n = 691); or received a planned, single dose of intrahepatic arterial yttrium 90 microspheres (n = 99); or received no therapy (n = 142) and were followed until death. After patients were stratified into subgroups defined by liver function (bilirubin <1.5 mg/dL or >1.5 mg/dL), tumor extension (the presence or absence of portal vein thrombosis), or the presence or absence of elevated α-fetoprotein, there was evidence of therapeutic equivalence in survival. The authors concluded that yttrium 90 microspheres were equivalent to chemoembolization for the regional treatment of unresectable HCC.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field